

1 **Does Influenza vaccination reduce the risk of contracting COVID-19?**

2 Francesc Alòs^a, Yoseba Cánovas Zaldúa^a, M Victoria Feijóo^b, José Luís Del-Val^{b,c},
3 Andrea Sanchez-Callejas^b. MA Colomer^d

4

5 ^aPrimary Health Center, CAP Passeig de Sant Joan, Barcelona, Spain

6 ^bBASIQ Unitat d'Avaluació, Sistemes d'Informació i Qualitat, Àmbit Barcelona Ciutat,
7 Institut Català de la Salut, Barcelona, España.

8 ^cUnitat de Suport a la Recerca Barcelona. Institut Universitari d'Investigació en Atenció
9 Primària Jordi Gol (IDIAP Jordi Gol), Barcelona.

10 ^dDepartment of Mathematics ETSEA, University of Lleida, 25198, Lleida, Spain.

11

12 **Corresponding author**

13 Dr. Francesc Alòs. Medical degree specializing in family and community medicine.

14 Catalan Institute of Health, Spain, fralos.bcn.ics@gencat.cat

15

16 **Abstract**

17

18 The concurrent timing of the COVID-19 pandemic and the seasonal occurrence of
19 influenza, makes it especially important to analyze the possible effect of the influenza
20 vaccine on the risk of contracting COVID-19, or in reducing the complications caused
21 by both diseases, especially in vulnerable populations. There is very little scientific
22 information on the possible protective role of the influenza vaccine against the risk of
23 contracting COVID-19, particularly in groups at high-risk of influenza complications.
24 Reducing the risk of contracting COVID-19 in high-risk patients (those with a higher
25 risk of infection, complications, and death) is essential to improve public well-being and
26 to reduce hospital pressure and the collapse of primary health centers. Apart from
27 overlapping in time, COVID-19 and flu share common aspects of transmission, so that
28 measures to protect against flu might be effective in reducing the risk of contracting
29 COVID-19.

30 In this study, we conclude that the risk of contracting COVID-19 is reduced if
31 patients are vaccinated against flu, but the reduction is small (0.22%) and therefore not
32 clinically important. When this reduction is analysed based on the risk factor suffered
33 by the patient, statistically significant differences have been obtained for patients with

34 cardiovascular problems, diabetics, chronic lung and chronic kidney, in all four cases
35 the reduction in the risk of contagion does not reach 1%.

36 It is worth highlighting the behaviour that is completely different from the rest of the
37 data for institutionalized patients. The data for these patients does not suggest a
38 reduction in the risk of contagion for patients vaccinated against the flu, but rather the
39 opposite, a significant increase of 6%.

40 Socioeconomic conditions, as measured by the MEDEA deprivation index, explain
41 increases in the risk of contracting COVID-19, and awareness campaigns should be
42 increased to boost vaccination programs.

43

44 Keywords: COVID-19; Influenza Vaccines; Comorbidity; Health Status Disparities;
45 Social Determinants of Health; Public Health.

46

47 **1. Introduction**

48 The COVID-19 pandemic of 2019 originated in the city of Wuhan, China, at the end of
49 December 2019. COVID-19 is an acute respiratory disease caused by the severe acute
50 respiratory syndrome coronavirus 2 (SARS-CoV-2) and spread rapidly worldwide,
51 posing a threat due to its virulence and the high rate of morbidity and mortality it causes
52 (Zhang et al., 2020; Mizumoto et al., 2020).

53

54 Many resources are being invested in measures to alleviate, or try to stop, the spread of
55 COVID-19. At first, it was thought that the transmission of the virus could be reduced
56 by widespread vaccination and that herd immunity would be achieved if the vaccinated
57 proportion of a population reached 70%. The current reality is that the rate of
58 vaccination varies significantly depending on the economic situation of a region, against
59 a backdrop of increasing global inequality. The percentage of people vaccinated against
60 COVID-19 in developed countries is much higher than in underdeveloped ones, running
61 the risk of prolonging the pandemic as new mutations appear in the developing world
62 (Tatar, et al., 2021; Liao, 2021).

63

64 Various studies have shown that the risks of infection and transmission of the disease do
65 not depend on whether the complete schedule of vaccines against COVID-19 has been
66 received (Kampf, 2021; Singanayagam et al., 2021). Vaccinated people have a lower

67 risk of serious illness but are still an important part of the pandemic. The ease with
68 which this disease is transmitted between vaccinated and unvaccinated people allows
69 new variants to emerge, with potentially lower percentages of protection with current
70 vaccines. There are currently 10 variants being monitored, of which two are ‘variants of
71 concern’ (European Center for Disease Prevention and Control). The high rate of
72 appearance of new variants generates a level of confusion at the health, social and
73 economic levels, the repercussions of which have prompted increased scientific research
74 into how the virus works and preventative measures and treatments that could mitigate
75 its effects on health and the spread of the pandemic. Prestigious journals have published
76 special issues dedicated exclusively to advances in research on SARS-CoV-2 (ASM
77 Journals; Nature, STOTEN, JMIR, JSSE, SAGE Journals, Arab Journal of Basic and
78 Applied Sciences, among others). Some of the published studies have looked at whether
79 effective measures for other types of viruses can reduce the effects of SARS-CoV-2.

80

81 Influenza and COVID-19 are two viral diseases with similar modes of transmission,
82 mainly through respiratory droplets emitted by both symptomatic and asymptomatic
83 sufferers (Yu et al., 2020; Rothe et al., 2020). They produce viral respiratory diseases
84 that can be clinically indistinguishable and cause serious complications, hospitalization,
85 and death, mainly in at-risk subgroups of the population, such as the elderly and those
86 with chronic disease (Keilman et al., 2019; Coleman et al., 2018). Also, because they
87 are viruses that mainly cause respiratory problems, their activity peak can occur during
88 the same time of year, namely the winter months in temperate countries.

89

90 Annual influenza vaccination is one of the most efficient and cost-effective strategies to
91 prevent and control influenza epidemics (WHO, 2012). Most developed countries have
92 annual seasonal influenza vaccine programs and similar means of tackling the virus
93 (European Centre for Disease Prevention and Control; Loerbroks et al., 2012;
94 Costantino and Vitale 2016).

95

96 Over time, the recommended age for influenza vaccination has gradually been lowered
97 to approximately 50 years of age as a more conservative strategy to address more of the
98 underlying chronic disease, unknown and unsuspected, above that age (Mereckiene et
99 al., 2012). The World Health Organization (WHO) has identified children from six
100 months to five years of age, pregnant women, those with chronic conditions and the

101 elderly as high-risk groups for flu and as candidate groups for the flu vaccine to reduce
102 infection, serious complications, and premature death (WHO, 2012). In Europe, annual
103 recommendations regarding the use of seasonal influenza vaccines vary between
104 Member States, but there is consensus that individuals with specific underlying
105 conditions and the elderly be vaccinated. In the USA, annual flu vaccination is
106 recommended for all persons aged six months or over who do not have a
107 contraindication (Rizzo et al., 2018).

108

109 Flu and COVID-19 affect populations unequally around the world, more severely
110 impacting groups with lower socioeconomic status, resulting in geographic inequalities
111 (Khanijahani et al., 2021; Martins, et al., 2020). Deprivation indices allow the lack of
112 economic and social resources to be quantified, making it possible to rank countries
113 from the least to the most deprived. They are constructed by combining various,
114 weighted, socioeconomic indicators, using a multivariate statistical model. They are
115 widely used tools in the analysis of health inequalities. Deprivation indices assess the
116 difficulty of access to material and social resources (education, work, housing, food,
117 culture, and social development) at levels that are considered acceptable in a society.
118 This expanded perspective goes beyond purely monetary aspects and is in line with
119 holistic models of health.

120

121 Vaccination campaigns have been important in the COVID-19 pandemic, both to
122 protect healthcare systems and the health of the population (Mendelson, 2020; Li et al.,
123 2020). International health organizations have been forceful in maintaining established
124 immunization programs (Pan American Health Organization, 2020; World Health
125 Organization, 2020). Most health professionals have spoken out in favor of
126 strengthening flu vaccination programs, arguing that increased flu vaccine coverage
127 could help improve the treatment of COVID-19 patients, facilitate diagnosis and reduce
128 pressure on healthcare systems, both in primary care centers and at the hospital level,
129 especially in intensive care units (ICUs) (Li et al., 2020). The reality of the 2020–2021
130 campaign has been to effectively ignore flu, although in general, the population
131 measures taken by governments and health services to protect against SARS-CoV-2
132 have also protected against flu. However, given the apparent difficulty of eradicating

133 SARS-CoV-2, it is expected that coming campaigns will have to address the
134 coexistence of both viruses.

135 The first Omicron variant from South Africa was notified to the WHO on November 24
136 2021. According to some researchers (Venkatakrishnan et al. 2021), the Omicron
137 variant of the virus causing COVID-19 probably acquired at least one of its mutations
138 by picking up a fragment of genetic material from another virus, possibly one causing
139 the common cold, which was present in the same infected cells. This variant presents
140 symptoms very similar to that of common flu and has a large number of mutations,
141 some of which are worrying, and faster rates of spread than previous variants have been
142 detected. If the research finally confirms the relationship between Omicron and the flu
143 virus, it becomes especially important to protect the population from the flu virus as
144 well.

145 Some studies have suggested that being vaccinated against flu could confer some
146 protection against SARS-CoV-2 infection, leading to reductions in hospitalizations, ICU
147 admissions and mortality (Vila-Córcoles, et al., 2020; Amato et al., 2020). Most studies
148 have been of the general population and based on small samples (Del Riccio et al.,
149 2020). Not all studies have found a significant association between the flu vaccine and
150 the risk of infection from SARS-CoV-2. Some authors (Noale et al., 2020) found a
151 partial relationship and/or a reduction in the risk of infection for people under 65 years
152 of age, while others (Pawlowski et al, 2021) have shown a stronger association in the
153 subgroup of people older 64 years old. Findings related to the possible relationship
154 between the flu vaccine and SARS-CoV-2 infection are insufficient and contradictory.
155 Additional studies to better quantify the relationship are needed to improve
156 understanding of the possible protective role of the flu vaccine on the spread of
157 COVID-19.

158 The main objective of this study was to determine the association between the seasonal
159 flu vaccine and the risk of contracting COVID-19 in those patients for whom the
160 seasonal flu vaccine is recommended, considering their risk level and the probability of
161 serious complications. This relationship should be observable in the different groups at
162 high-risk of flu complications, including the subgroup of people over 60 years of age
163 who do not present any other risk factor for flu complications. A further objective was

164 to assess the probability of contracting COVID-19 in people vaccinated against flu in
165 relation to different levels of deprivation.

166

167 **2. Materials and methods**

168 **2.1. Data**

169 Our database comprised all patient records in the high-risk groups for flu complications
170 who were recommended flu vaccination in the 2020–2021 vaccination campaign in the
171 primary care units of the Gerencia Territorial de Barcelona (GTB) ; Institut Català de la
172 Salut (ICS), between 15 October 2020 and 15 March 2021. Patients with a history of
173 contracting COVID-19 before 15 October 2021 were excluded from the database, as
174 well as those with a register of COVID-19 before the date of their flu vaccination.

175

176 Institutionalized patients (5,191 people living in nursing homes) were studied
177 separately, because their conditions, environment and habits were different from the rest
178 of the 429,537 patients (193,072 patients and 236,465 patients, vaccinated and not
179 vaccinated against flu, respectively). The flu vaccines administered were the trivalent
180 vaccine that included the B virus represented B/Colorado/06/2017 (lineage
181 B/Victoria/2/87), A/Brisbane/02/2018 (H1N1)pdm09 and A/Kansas/ 14/2017 (H3N2) –
182 and the quadrivalent vaccines which included the above together with the
183 B/Phuket/3073/2013 strain (lineage B/Yamagata/16/88).

184

185 The information related to flu vaccination and diagnosis of COVID-19 came from the
186 computerized clinical patient history records. The data were stored in a pseudonymized
187 database containing age, gender, risk factor for flu vaccination, flu vaccine receipt,
188 incidence of COVID-19 and the MEDEA deprivation index. The MEDEA deprivation
189 index (Mortality in small Spanish areas and Socioeconomic and Environmental
190 Inequalities) has been used in Spain since 2007 to analyze health inequalities in small
191 parts of urban areas, and for the identification and prioritization of territories of special
192 socioeconomic vulnerability (Domínguez-Berjón et al., 2008).

193

194 The sample size used was larger than strictly necessary to detect clinically significant
195 differences. In many cases, the inference tests that were used can give statistically
196 significant differences that are not clinically important.

197

198 **2.2. Statistical analysis**

199

200 The data analysis was divided into three phases. In the first phase, the global level was
201 analysed to detect any significant statistical differences between the risk of SARS-CoV-
202 2 infection between people vaccinated against flu and those not vaccinated, according to
203 age. Next, we looked to see whether the risk factor for flu complications determined the
204 effect of the flu vaccine on the risk of contracting COVID-19. Finally, we examined
205 whether a patient's level of deprivation affected either the probability of being
206 vaccinated against flu and/or the risk of contracting COVID-19.

207 A descriptive study was carried out to estimate the proportion of people infected with
208 SARS-CoV-2 who were vaccinated against flu. To study whether these differences were
209 statistically significant, a unilateral proportions test was performed to analyze whether
210 the flu vaccine could reduce the risk of contracting COVID-19.

211 All statistical analyses were performed using the R Core package (R Core 2018,
212 <https://www.R-project.org/>).

213

214 **3. Ethical considerations.**

215

216 This study followed the standards of Good Clinical Practice and the principles of the
217 Declaration of Helsinki. The project had the approval of the Clinical Research Ethics
218 Committee of the Institut d'Investigació en Atenció Primària (IDIAP) Jordi Gol
219 (reference 20/242-PCV). The confidentiality and anonymity of the patient data included
220 in the study conformed with Regulation 2016/678 of the European Parliament and of the
221 Council of 27/2016 on Data Protection and Organic Law 3/2018.

222

223 **4. Results**

224 **4.1 Relationship between vaccination against flu and SARS-CoV-2 infection.**

225 Of the 429,537 people in the database, 44.95% were vaccinated against flu and 56.80%
226 were women (Table 1). The percentage of people vaccinated against flu varied with age,
227 with people over 80 years of age being most likely to be vaccinated (61.92%). The
228 percentage of women vaccinated against flu was 56.80%; on average 12 percentage
229 points higher than men, and also higher than in all other age groups, except those under
230 15 years of age.

231

232

233 Table 1. Percentage of people contracting COVID-19 who were vaccinated against flu,
234 according to age and sex.

Age	Sample size	Vaccinated against flu (%)	Vaccinated women (%)
0-14	8,348	49.4	48
15-20	5,578	21.3	23.2
21-30	125,40	16.1	21
31-40	18,991	21.9	27.2
41-50	31,466	25	28.1
51-60	58,278	31.5	33.9
61-70	122,390	43.1	43.6
71-80	100,797	58	56.8
> 80	71,149	61.9	59.8
Total	429,537	44.95	56.8

235

236 On average, people contracting COVID-19 represented 4.06% of those vaccinated
237 against flu and 4.44% of those not vaccinated (Fig. 1). Globally, the percentage of
238 people contracting COVID-19 was higher in people not vaccinated against flu, this
239 difference being statistically significant ($P < 0.001$) but not clinically important (odds
240 ratio 0.91, 95% CI 0.89–0.94; $P < 0.001$). When this percentage was calculated by
241 age, lower values of COVID-19 incidence were not observed in all cases for those
242 vaccinated against flu (Fig. 2). For those under 60 years of age the difference was not

243 statistically significant. However for those over 60, the percentage of those vaccinated
 244 against flu who contracted COVID-19 was higher than in the unvaccinated group, the
 245 difference being statistically significant (Table 2), although these statistically significant
 246 differences were not clinically important.

247

248

249

250


251 Table 2. Probability of SARS-CoV-2 infection, based on flu vaccination status (FVS),
 252 stratified by age (over or under 60 years of age).

	Probability of SARS-CoV-2 infection		<i>P</i> -value
	No FVS	Yes FVS	
Total population	4.45%	4.23%	< 0.001
< 60 years old	5.83%	5.70%	0.3585
≥ 60 years old	3.62%	3.72%	< 0.001

253

254

Covid-19 according to flu vaccination status (FVS)




255

256 Figure 2. Probability of contracting COVID-19 depending on whether or not the patient
257 had received the flu vaccine.

258 **4.2 SARS-CoV-2 infection levels according to flu risk group and vaccination** 259 **against flu.**

260 In most age groups, the higher the number of different risk factors for flu complications
261 that a person presents, the higher the probability that they will have been vaccinated
262 against flu (Fig. 3). This can mask the effect of the flu vaccine on the risk of contracting
263 COVID-19, since these groups are those most susceptible to SARS-CoV-2 infection.



264
265 Figure 3. Proportion of people vaccinated against flu according to age and the number
266 of risk factors for flu complications.

267
268 When the relative risk of contracting COVID-19 was examined in relation to the various
269 risk factors for flu complications (Table 3), the differences observed were not
270 statistically significant for most factors. For those factors that did show significant
271 effects, the differences were small and not clinically significant. Statistically significant
272 differences were observed for patients with chronic cardiovascular diseases, diabetes
273 mellitus and lung and kidney problems.

274 We also examined whether there were significant differences in the risk of contracting
275 COVID-19 according to the number of risk factors for flu complications presented by

276 each patient (Table 4). The differences observed were not statistically significant,
 277 except for patients who only presented with a single risk factor. At the mean level of
 278 risk factors, 0.7% more unvaccinated people contracted flu, and this value was clinically
 279 significant.

280

281 Table 3. Percentage of people contracting COVID-19 according to whether or not they
 282 had been vaccinated for flu (FVS). *P*-value of the proportion comparison test.

Risk factor	Sample size	Proportion of people contracting COVID-19 not FVS / FVS (<i>P</i> -value)		Relative risk	
		All	> 59 years old	All	> 59 years old
Chronic cardiovascular diseases	231,853	4.6/4 (< 0.001)	3.9/3.8 (0.248)	0.87	0.97
Digestive problems	8,699	5.1/4.6 (0.2699)	4.2/4.3 (0.8851)	0.90	1.02
Mellitus diabetes	75,986	5/4.5 (< 0.001)	4.5/4.2 (0.0615)	0.90	0.93
Pregnant women	3,688	5.8/6.5 (0.3799)		1.12	
Immunodeficiencies	6,882	5.2/4.5 (0.2094)	3.2/4 (0.2416)	0.87	1.25
Malformations	1,135	3.5/4.8 (0.2971)	4.2/2.3 (0.4831)	1.37	0.55
Chronic kidney disease	34,597	4.7/4.3 (0.0457)	4.6/4.2 (0.0967)	0.91	0.91
Neoplasms	4,926	4.9/4.1 (0.1535)	4/4 (0.9901)	0.84	1.00
Neurological diseases	6,525	4.5/4.7 (0.8261)	4.8/4.7 (0.8706)	1.04	0.98
Chronic lung	92,187	5.4/4.8 (< 0.001)	4.2/4.4 (0.001)	0.89	1.05

diseases		0.001)	(0.4177)		
Hematologic disorders	6,477	5.2/4.3 (0.0826)	4.2/3.8 (0.5704)	0.83	0.90
Organ transplant	1,668	6.1/5.4 (0.5284)	5.1/4.7 (0.7882)	0.89	0.92
HIV infection	2,245	2.8/3.2 (0.6069)	2.3/2.8 (0.7066)	1.14	
Living in a nursing home	5,191	-----	6.6/12.6 (< 0.001)		1.91
Older than 60 years without other RF.	98,570	3.3/3.4 (0.3701)		1.03	
Any age with RF different from the average for their age	330,967	4.9/4.2 (< 0.001)	3.9/3.8 (0.1139)	0.86	0.97

283

284

285


286 Table 4. Percentage of people contracting COVID-19, depending on the number of risk
 287 factors for flu complications, according to whether they had been vaccinated against flu
 288 (FVS).

Number of risk factors for flu complications	Probability of SARS-CoV-2 infection		P-value
	No FVS	Yes FVS	
0	3.3	3.4	0.3701
1	4.9	4.2	< 0.001
2	4.5	4.4	0.6594
3	5.0	5.2	0.5417
≥ 4	7.2	6.7	0.4702

289

290 **4.3 Relationships between the MEDEA deprivation index, flu vaccination and**
291 **SARS-CoV-2 infection.**

292 The MEDEA index values were grouped into percentiles from 10 to 100. First, we
293 examined whether the proportion of people vaccinated against flu and contracting
294 COVID-19 varied depending on the level of deprivation as measured by the MEDEA
295 index. The percentages of people with high risk factor scores for flu complications
296 vaccinated against flu and contracting COVID-19 were similar for the different
297 MEDEA index values, except in the case of high MEDEA values, where the probability
298 of being vaccinated was lower and the risk of presenting with COVID-19 was higher
299 (Fig. 4).




300

301 Figure 4. Relationship between the *P* of people vaccinated against flu and presenting
302 with COVID-19, and the MEDEA index.

303

304 The proportion of people contracting COVID-19 at different MEDEA index values,
305 according to whether they were vaccinated against flu (Fig. 5), was higher when they
306 were not vaccinated against flu and at higher MEDEA index values. The differences
307 were statistically significant ($P < 0.001$) and clinically important.




308

309 Figure 5. Proportion of people contracting COVID-19 according to whether or not they
 310 had been vaccinated against flu, and the MEDEA index.

311

312 The probability of presenting with COVID-19 increases with increasing MEDEA index
 313 value (Fig. 6). People under 60 years of age showed higher Covid-19 incidence rates
 314 than people 60 years of age or older, at high MEDEA index values.

315



316

317 Figure 6. Probability of contracting COVID-19 depending on whether or not a person
 318 has been vaccinated against flu, and the size of the MEDEA index. For people above
 319 and below 60 years of age.

320

321 **5. Discussion**

322 In general, it was observed that people vaccinated against flu had a lower risk of
323 presenting with COVID-19 than those who had not been vaccinated (4.44% vs. 4.06%,
324 respectively), but the difference was not clinically significant. Analyzing the data by
325 age, there was no consistent reduction in the probability of presenting with COVID-19
326 in those vaccinated against flu: in two of the age ranges studied there was a reduced risk
327 of contracting COVID-19: in four age ranges there was an increase; and in three age
328 ranges the differences were practically nil.

329 The odds ratio of contracting COVID-19 in patients who have been vaccinated against
330 flu was 0.91, far from the value of 0.76 obtained by Conlon et al. (2021) in a group of
331 4.5 million patients from Michigan.. In our study, the sample consisted of patients with
332 a high-risk of flu complications, who were recommended to take vaccination against flu,
333 while in the sample examined by Conlon et al. the sample group was not restricted to
334 any condition or risk group for flu. In most cases, people who are at higher risk of
335 complications from flu are also at higher risk of contracting COVID-19, who could take
336 stronger measures to protect themselves from COVID-19, unlike the population without
337 risk factors.

338 In a sample of 6,856 employees of a Dutch hospital, Debisarun et al. (2021) observed
339 relative reductions in the risk of contracting COVID-19 of 37% and 49% after flu
340 vaccination during the first and second waves of the COVID-19 pandemic, respectively,
341 values similar to the 38% found by Vila Córcoles et al. (2020). The reduction in the
342 global risk of contracting COVID-19 after flu vaccination in our study was only 9%.

343 Patients with comorbidities such as high blood pressure, diabetes mellitus, chronic
344 obstructive pulmonary disease, heart disease, neoplasms and HIV have a higher risk of
345 contracting COVID-19 (Ejaz et al., 2020). Patients with chronic obstructive pulmonary
346 disease develop substantial and severe symptoms and suffer comparatively higher
347 mortality rates. Analyzing the effect of the flu vaccine based on the risk factors for flu
348 complications, we observed reductions in the risk of contracting COVID-19 for patients
349 with cardiovascular diseases (0.6%), pulmonary diseases (0.6%), diabetes (0.5%) and
350 chronic kidney disease (0.4%), results which corroborate those of Vila Córcoles et al.
351 (2020). These four risk factors for flu complications account for more than 80% of the
352 total population at risk. Reducing the risk of contracting COVID-19 in these patient
353 groups is important because they have a higher risk of mortality from COVID-19
354 (Ssentongo et al., 2020). No statistically significant differences were observed between

355 the rest of the risk factors for flu complications. The most prevalent risk factors for flu
356 complications have strict control and monitoring programs that are likely to reduce the
357 positive effect of the flu vaccine.

358 When only one risk factor is present, if the patient was vaccinated for flu the probability
359 of contracting COVID-19 decreased by 0.7%, while no differences were observed in
360 cases presenting more than one risk factor. The number of risk factors increased with
361 age, and as the risk factors increased the probability of presenting with COVID-19
362 increased, with no statistically significant differences being observed between those
363 vaccinated against flu and those not vaccinated. This result could be explained by the
364 fact that an increase in risk factors increases a patient's susceptibility to contracting or
365 becoming infected with other pathologies.

366 Nursing homes for the elderly are spaces that facilitate the spread of contagious diseases
367 (Liotta et al., 2020; Lansbury et al., 2017). The proportion of institutionalized patients
368 contracting COVID-19 increased significantly in the case of those vaccinated for flu
369 (12.6%) compared to those not vaccinated (6.6%). This could be explained by the fact
370 that institutionalized people are generally those at high-risk and have multiple risk
371 factors for flu complications, as well as for the SARS-CoV-2 infection itself and live in
372 an environment which favors the spread of respiratory pathogens. (Jordan and Hawker,
373 2006).

374 Various studies have evaluated the effectiveness of the flu vaccine in people over 65
375 years of age and concluded that the effect may be mild or moderate in preventing flu-
376 like illnesses (Lansbury et al., 2017; Monto et al., 2001). Flu outbreaks occur even in
377 nursing homes with high vaccination rates in years when there is little difference
378 between the circulating strain and the vaccine, raising questions about the efficacy of
379 the flu vaccine, especially in frail elderly people who may not be able to acquire an
380 adequate immune response, which might explain the results obtained in our study.

381 Conditions in nursing homes for the elderly increase contact and interaction between
382 residents, increasing the speed of spread of SARS-CoV-2. The age of institutionalized
383 patients, together with the day-to-day routines in nursing homes, means that this group
384 of patients behave and respond differently from others when protective measures are
385 applied (Liotta et al., 2020). Likewise, patients who live in nursing homes have
386 vulnerability characteristics that provide a favorable environment for the rapid spread of

387 the flu virus and other respiratory pathogens. (Lansbury et al., 2017). Infections can be
388 introduced by new or transferred staff, visitors or residents, and outbreaks of flu in such
389 settings can have devastating consequences for residents, as well as place additional
390 pressures on health services. In the coming decades, the population trend is for the
391 number of elderly people to increase, so it is likely that the number residences for the
392 elderly will also increase. The need to improve management, prevention and control of
393 infectious diseases will therefore become especially important if the impact of new and
394 existing contagious diseases is to be minimized. This study reinforces the importance of
395 promoting changes in nursing homes and in reinforcing general measures, including
396 vaccination against both flu and COVID-19, not only in patients institutionalized in
397 nursing homes, but also in staff and visitors.

398 The COVID-19 pandemic has had a range of impacts, and populations with the poorest
399 socioeconomic status have been the most affected. Populations with the greatest
400 deprivation (measured according to the MEDEA index), have a lower percentage of flu
401 vaccination and a greater probability of presenting with COVID-19, apparently
402 consistent with results published by some authors (Mena et al., 2021; Riou et al., 2021;
403 Hawkins et al., 2020; Chang et al., 2021; Morrissey et al., 2021). This relationship may
404 be due to the fact that the highest levels of deprivation include the worst socioeconomic
405 conditions, housing characteristics, types of employment and access to education and
406 culture. In addition, deprived populations tend to neglect population vaccination
407 programs, thus increasing their probability of contracting COVID-19. Deprivation is
408 clearly a very important factor in explaining the unequal percentages of SARS-CoV-2
409 infection and the implementation of flu vaccination programs in certain urban areas or
410 geographic regions.

411

412 The COVID-19 pandemic has caused both hospital and primary care medical services to
413 become overburdened all over the world. The continuation of effective immunization
414 programs is essential to protect people against diseases and outbreaks that can be
415 prevented using vaccines, and so reduce the burden of respiratory diseases during the
416 period in which both COVID-19 and flu may overlap. This study also reinforces the
417 importance of preventive measures against both diseases at the same time. The results
418 are especially important in the light of the probability that we will have to live with both
419 viruses for a long time to come.

420 **6. Conclusion**

421 Patients in high-risk groups for flu complications have a lower risk of contracting
422 COVID-19. The differences are statistically significant, but not very relevant from the
423 clinical point of view. A reduced risk of contracting COVID-19 has been observed in
424 patients with cardiovascular disease, lung disease, chronic kidney disease and diabetes.
425 These four risk factors for flu complications account for more than 80% of the total
426 population at risk. Reducing the risk of contracting COVID-19 in these groups of
427 patients is important because they are patients with a higher risk of mortality from
428 COVID-19. Finally, we observed that increasing levels of socioeconomic deprivation,
429 as measured by the MEDEA index, increase the risk of contracting COVID-19 in
430 populations not vaccinated against flu and in patients with a higher risk of contracting
431 COVID-19.

432

433 **Bibliografia**

- 434 Amato, M., Werba, J.P., Frigerio, B., Coggi, D., Sansaro, D., Ravani, A., Ferrante, P.,
435 Veglia, F., Tremoli, E., Baldassarre, D., 2020. Relationship between Flu Vaccination
436 Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study. *Vaccines*, 8(3),
437 535, <https://doi.org/10.3390/vaccines8030535>.
- 438 Chang, H.Y., Tang, W., Hatef, E., Kitchen, C., Weiner, J., Hadi, K., 2021. Differential
439 impact of mitigation policies and socioeconomic status on COVID-19 prevalence and
440 social distancing in the United States. *BMC Public Health* 21, 1140.
441 <https://doi.org/10.1186/s12889-021-11149-1>.
- 442 Coleman, B.L., Fadel, S.A., Fitzpatrick, T., Thomas, S.M., 2018. Risk factors for
443 serious outcomes associated with flu illness in high- versus low- and middle-income
444 countries: Systematic literature review and meta-analysis. *Flu and other respiratory*
445 *viruses*. 12(1):22-29. <https://doi.org/10.1111/irv.12504>.
- 446 Conlon, A., Ashur, C., Washer, L., Eagle, K.A., Hofmann Bowman, M.A., 2021. Impact
447 of the flu vaccine on COVID-19 infection rates and severity. *American Journal of*
448 *Infection Control*, 49(6), 694-700. <https://doi.org/10.1016/j.ajic.2021.02.012>.
- 449 Costantino, C., Vitale, F., 2016. Flu vaccination in high-risk groups: a revision of
450 existing guidelines and rationale for an evidence-based preventive strategy. *Journal of*
451 *preventive medicine and hygiene*, 57(1), E13–E18.
- 452 Debisarun, P.A., Gössling, K.L., Bulut, O., Kilic, G., Zoodsma, M., Liu, Z., Oldenburg,
453 M., Rüchel, N., Zhang, B., Xu, Ch.J., Struycken, P., Koeken, V.A.C.M., Domínguez-
454 Andrés, J., Simone J C F M Moorlag, S.J.C.F.M., Taks, E., Ostermann, P.N., Müller,
455 L., Schaal, H., Adams, O., Borkhardt, A., Ten Oever, J., Crevel, R., Li, Y., Netea,

- 456 M.G.,2021. Induction of trained immunity by flu vaccination - impact on COVID-19.
457 Plos Pathogens. <https://doi.org/10.1371/journal.ppat.1009928>
- 458 Del Riccio, M., Lorini, C., Bonaccorsi, G., Paget, J., Caini, S., 2020. The Association
459 between Flu Vaccination and the Risk of SARS-CoV-2 Infection, Severe Illness, and
460 Death: A Systematic Review of the Literature. *Int. J. Environ. Res. Public Health* 2020,
461 17(21), 7870. <https://doi.org/10.3390/ijerph17217870>.
- 462 Domínguez-Berjón MF, Borrell C, Cano-Serral G, et al. Construcción de un índice de
463 privación a partir de datos censales en grandes ciudades españolas (Proyecto MEDEA).
464 *Gac Sanit.* 2008;22:179-87.
- 465 Ejaz, H., Alsrhani, A., Zafar, A., Javed, H., Junaid, K., Abdalla, A.E.,Abosalif, K.O.A.,
466 Ahmed, Z., Younas, S., 2020.COVID-19 and comorbidities: Deleterious impact on
467 infected patients,
- 468 World Health Organization. Vaccines against flu. WHO position paper - November
469 2012. *Relev Epidemiol Hebd.* 2012;87:461-476.
- 470 World Health Organization. United Nations Children’s Fund. In Immunization in the
471 Context of COVID-19 Pandemic: Frequently Asked Questions (FAQ), 16 April 2020;
472 World Health Organization: Geneva, Switzerland, 2020.
- 473 European Centre for Disease Prevention and Control. An agency of the European
474 Union. <https://www.ecdc.europa.eu/en/covid-19/variants-concern>. (accessed 7
475 September 2021).
- 476 Hawkins,R.B., Charles, E.J., Mehaffey, J.H. Socio-economic status and COVID-19–
477 related cases and fatalities. *Public Health*, 189, 129-134.
478 <https://doi.org/10.1016/j.puhe.2020.09.016>.
- 479 Kampf, G., 2021. COVID-19: stigmatising the unvaccinated is not justified. *The Lancet*
480 *Infectious Diseases*. 398, ISSUE 10314, P1871.
- 481 Keilman, L.J., 2019. Seasonal Flu (Flu). *Nursing Clinics of North America*, 54, 227-
482 243. <https://doi.org/10.1016/j.cnur.2019.02.009>.
- 483 Khanijahani A, Iezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic
484 review of racial/ethnic and socioeconomic disparities in COVID-19. *Int J Equity Health*.
485 2021;20(1):248. Published 2021 Nov 24. doi:10.1186/s12939-021-01582-4
- 486 Lansbury, L.E., Brown, C.S., Nguyen-Van-Tam, J.S., 2017. Flu in long-term care
487 facilities. *Flu Other Respir Viruses*. 11(5):356-366. <https://doi.org/10.1111/irv.12464>.
- 488 Li, Q.,Tang, B., Bragazzi, N.L., Xiao, Y.,Wu, J., 2020. Modeling the impact of mass flu
489 vaccination and public health interventions on COVID-19 epidemics with limited
490 detection capability. *Mathematical Biosciences*. 325, 108378.
491 <https://doi.org/10.1016/j.mbs.2020.108378>.
- 492 Liao, T.F., 2021 Social and economic inequality in coronavirus disease 2019
493 vaccination coverage across Illinois counties. *Sci Rep* 11, 18443.
494 <https://doi.org/10.1038/s41598-021-97705-6>.

- 495 Liotta, G., Marazzi, M.C., Orlando, S., Palombi, L., 2020. Is social connectedness a risk
496 factor for the spreading of COVID-19 among older adults? The Italian paradox. *PLOS*
497 *ONE* 15(5): e0233329. <https://doi.org/10.1371/journal.pone.0233329>
- 498 Loerbroks,A., Stock, C., Bosch, J.A., Litaker, D.G., Apfelbacher,C.J., 2012. Flu
499 vaccination coverage among high-risk groups in 11 European countries, *European*
500 *Journal of Public Health*, 22(4), 562–568. <https://doi.org/10.1093/eurpub/ckr094>.
- 501 Jordan, R.E., Hawker, J.I.,2006. Flu in elderly people in care homes. *BMJ*.
502 333(7581):1229-1230. <https://doi.org/10.1136/bmj.39050.408044.80>.
- 503 Martins LD, da Silva I, Batista WV, Andrade MF, Freitas ED, Martins JA. How socio-
504 economic and atmospheric variables impact COVID-19 and flu outbreaks in tropical
505 and subtropical regions of Brazil. *Environ Res.* 2020;191:110184.
506 doi:10.1016/j.envres.2020.110184
- 507 Mena, G.E., Martinez, P.P., Mahmud, A.S., Marquet, P.A., Buckee, C.O., Santillana,
508 M., 2021. Socioeconomic status determines COVID-19 incidence and related mortality
509 in Santiago, Chile. *Science.* 28;372(6545).
510 <https://doi.org/10.1101/2021.01.12.21249682>.
- 511 Mendelson, M., 2020. Could enhanced flu and pneumococcal vaccination programs
512 help limit the potential damage from SARS-CoV-2 to fragile health systems of southern
513 hemisphere countries this winter? *International Journal of Infectious Diseases.* 94: 32-
514 33. <https://doi.org/10.1016/j.ijid.2020.03.030>.
- 515 Mereckiene, J., Cotter, S., Weber, J.T., Nicoll, A., D'Ancona, F., Lopalco, P.L.,
516 Johansen, K., Wasley, A.M., Jorgensen, P., Lévy-Bruhl, D., Giambi, C., Stefanoff, P.,
517 Dematte, L., O'Flanagan, D., 2012. Flu A(H1N1)pdm09 vaccination policies and
518 coverage in Europe. *Eurosurveillance.*
519 <https://www.eurosurveillance.org/content/10.2807/ese.17.04.20064-en>.
- 520 Mizumoto, K., Kagaya, K., Chowell, G., 2020. Effect of a wet market on coronavirus
521 disease (COVID-19) transmission dynamics in China, 2019–2020. *Int. J. Infect. Dis.* 97,
522 96–101.
- 523 Monto, A.S., Hornbuckle, K., Ohmit, S.E., 2001. Flu Vaccine Effectiveness among
524 Elderly Nursing Home Residents: A Cohort Study, *American Journal of Epidemiology.*
525 154(2), 155-160, <https://doi.org/10.1093/aje/154.2.155>.
- 526 Morrissey K, Spooner F, Salter J, Shaddick G. Area level deprivation and monthly
527 COVID-19 cases: The impact of government policy in England. *Soc Sci Med.*
528 2021;289:114413. doi:10.1016/j.socscimed.2021.114413
- 529 Noale, M., Trevisan, C., Maggi, S., Antonelli Incalzi, R., Pedone, C., Di Bari, M.,
530 Adorni, F., Jesuthasan, N., Sojic, A., Galli, M., Giacomelli, A., Molinaro, S., Bianchi,
531 F., Mastroianni, C., Prinelli, F., 2020. The Association between Flu and Pneumococcal
532 Vaccinations and SARS-Cov-2 Infection: Data from the EPICOID19 Web-Based
533 Survey. *Vaccines*, 8(3), 471. <https://doi.org/10.3390/vaccines8030471>.

- 534 Pan American Health Organization. The Immunization Program. In the Context of the
535 COVID-19 Pandemic. Version 2: 24 April 2020; Pan American Health Organization
536 (PAHO): Washington, DC, USA, 2020.
- 537 Pawlowski, C., Puranik, A., Bandi, H., Venkatakrishnan, A.J., Agarwal, V., Kennedy,
538 R., O'Horo, J.C., Gores, G.J., Williams, A.W., Halamka, J., Badley, A.D.,
539 Soundararajan, V., 2021. Exploratory analysis of immunization records highlights
540 decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations.
541 *Sci Rep* 11, 4741. <https://doi.org/10.1038/s41598-021-83641-y>.
- 542 R Core Team (2018). R: A language and environment for statistical computing. R
543 Foundation for Statistical Computing, Vienna, Austria. Available online at
544 <https://www.R-project.org/>.
- 545 Singanayagam, A., Hakki, S., Dunning, J., Madon, K.J., Crone, M.A., Koycheva, A.,
546 Derqui-Fernandez, N., Barnett, J.L., Whitfield, M.G., Varro, R., Charlett A., Kundu, R.,
547 Fenn, J., Cutajar, J., Quinn, V., Conibear, E., Barclay, W., Freemont, P.S., Taylor, G.P.,
548 Ahmad, S., Zambon, M., Ferguson, N.M., Lalvani, A., 2021. Community transmission
549 and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and
550 unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. *The*
551 *Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(21\)00648-4](https://doi.org/10.1016/S1473-3099(21)00648-4).
- 552 Ssentongo, P., Ssentongo, A.E., Heilbrunn, E.S., Ba, D.M., Chinchilli, V.M., 2020.
553 Association of cardiovascular disease and 10 other pre-existing comorbidities with
554 COVID-19 mortality: A systematic review and meta-analysis. *PlosOne*.
555 <https://doi.org/10.1371/journal.pone.0238215>.
- 556 Riou, J., Panczak, R., Althaus, C.L., Junker, C., Perisa, D., Schneider, K., Criscuolo,
557 N.G., Low, N., Egger, M., 2021. Socioeconomic position and the COVID-19 care
558 cascade from testing to mortality in Switzerland: a population-based analysis. *The*
559 *Lancet Public Health*, [https://doi.org/10.1016/s2468-2667\(21\)00160-2](https://doi.org/10.1016/s2468-2667(21)00160-2).
- 560 Rizzo, C., Rezza, G., Ricciardi, W., 2018. Strategies in recommending flu vaccination
561 in Europe and US. *Hum Vaccin Immunother*. 14(3):693-698.
562 <https://doi.org/10.1080/21645515.2017.1367463>.
- 563 Rothe, C. et al., 2020. Transmission of 2019-ncov infection from an asymptomatic
564 contact in germany. *N Engl J Med* 382,970–971.
565 <https://www.nejm.org/doi/full/10.1056/NEJMc2001468>.
- 566 Tatar, M., Shoorekchali, J. M., Faraji, M. R., & Wilson, F. A., 2021. International
567 COVID-19 vaccine inequality amid the pandemic: Perpetuating a global crisis?. *Journal*
568 *of global health*, 11, 03086. <https://doi.org/10.7189/jogh.11.03086>.
- 569 Venkatakrishnan, A., Anand, P., Lenehan, P., Suratekar, R., Raghunathan, B., Niesen,
570 M. J., Soundararajan, V., 2021. Omicron variant of SARS-CoV-2 harbors a unique
571 insertion mutation of putative viral or human genomic origin.
572 <https://doi.org/10.31219/osf.io/f7txy>.
- 573 Vila-Córcoles, Á., Ochoa-Gondar, O., Torrente-Fraga, C., Vila-Rovira, Á., Satué-
574 Gracia, E., Hospital-Guardiola, I., de Diego-Cabanes, C., Gómez-Bertomeu, F.;

- 575 Basora-Gallisà, J., 2020. Evaluation of incidence and risk profile for suffering Covid-19
576 infection by underlying conditions among middle-aged and older adults in Tarragona.
577 *Rev. Esp. Salud Publica.* 94:e202006065.
- 578 Vila-Córcoles A, Ochoa-Gondar O, Satué-Gracia EM, et al. Influence of prior
579 comorbidities and chronic medications use on the risk of COVID-19 in adults: a
580 population-based cohort study in Tarragona, Spain. *BMJ Open.* 2020;10(12):e041577.
581 Published 2020 Dec 10. doi:10.1136/bmjopen-2020-041577
- 582 Yu, P., Zhu, J., Zhang, Z., Han, Y., Huang, L., 2020. A familial cluster of infection
583 associated with the 2019 novel coronavirus indicating potential person-to-person
584 transmission during the incubation period. *The Journal of Infectious Diseases*, 221,
585 1757–1761. <https://doi.org/10.1093/infdis/jiaa077>
- 586 Zhang, X., Chen, X., Zhang, Z., Roy, A., She, Y., 2020. Strategies to trace back the
587 origin of COVID-19. *J. Infect.* 80, e39–e40.